CellSource Co., Ltd. (4880.T)
JPY 651.0
(-0.15%)
JPY 651.0
(-0.15%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 6.87 Billion JPY | 49.57% |
| 2022 | 4.59 Billion JPY | 36.68% |
| 2021 | 3.36 Billion JPY | 43.08% |
| 2020 | 2.35 Billion JPY | 27.68% |
| 2019 | 1.84 Billion JPY | 164.31% |
| 2018 | 697.01 Million JPY | 112.88% |
| 2017 | 327.42 Million JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 6.86 Billion JPY | -0.17% |
| 2024 Q2 | 6.87 Billion JPY | 1.01% |
| 2024 Q1 | 6.8 Billion JPY | -1.05% |
| 2023 Q4 | 6.87 Billion JPY | 37.11% |
| 2023 FY | 6.87 Billion JPY | 49.57% |
| 2023 Q3 | 5.01 Billion JPY | 4.26% |
| 2023 Q2 | 4.81 Billion JPY | 8.96% |
| 2023 Q1 | 4.41 Billion JPY | -3.98% |
| 2022 Q2 | 3.54 Billion JPY | 10.7% |
| 2022 Q1 | 3.2 Billion JPY | -4.83% |
| 2022 Q4 | 4.59 Billion JPY | 20.24% |
| 2022 FY | 4.59 Billion JPY | 36.68% |
| 2022 Q3 | 3.82 Billion JPY | 7.89% |
| 2021 Q1 | 2.44 Billion JPY | 4.02% |
| 2021 Q2 | 2.75 Billion JPY | 12.41% |
| 2021 Q3 | 2.99 Billion JPY | 9.05% |
| 2021 Q4 | 3.36 Billion JPY | 12.21% |
| 2021 FY | 3.36 Billion JPY | 43.08% |
| 2020 FY | 2.35 Billion JPY | 27.68% |
| 2020 Q1 | 2.07 Billion JPY | 12.62% |
| 2020 Q4 | 2.35 Billion JPY | 10.21% |
| 2020 Q3 | 2.13 Billion JPY | 0.55% |
| 2020 Q2 | 2.12 Billion JPY | 2.31% |
| 2019 Q3 | 729.27 Million JPY | 0.0% |
| 2019 Q4 | 1.84 Billion JPY | 152.61% |
| 2019 FY | 1.84 Billion JPY | 164.31% |
| 2018 FY | 697.01 Million JPY | 112.88% |
| 2017 FY | 327.42 Million JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | -4.407% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -467.904% |
| GNI Group Ltd. | 62.39 Billion JPY | 88.974% |
| Linical Co., Ltd. | 18.53 Billion JPY | 62.892% |
| Trans Genic Inc. | 9.81 Billion JPY | 29.877% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | -22.108% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 0.956% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | -18.283% |
| AnGes, Inc. | 28.89 Billion JPY | 76.189% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -693.259% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 95.624% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -325.047% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | -35.661% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | -58.159% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -182.784% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -189.872% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 0.729% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -292.801% |
| Kidswell Bio Corporation | 5.08 Billion JPY | -35.28% |
| PeptiDream Inc. | 67.12 Billion JPY | 89.751% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -237.143% |
| Ribomic Inc. | 3.54 Billion JPY | -93.945% |
| SanBio Company Limited | 5.04 Billion JPY | -36.306% |
| Healios K.K. | 15.15 Billion JPY | 54.604% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -459.211% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | -128.108% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -366.69% |
| StemRIM | 9.08 Billion JPY | 24.232% |
| FunPep Company Limited | 2.49 Billion JPY | -176.169% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | -162.72% |
| Stella Pharma Corporation | 3.82 Billion JPY | -80.068% |
| TMS Co., Ltd. | 3.55 Billion JPY | -93.536% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | -19.048% |
| Cuorips Inc. | 6.18 Billion JPY | -11.237% |
| K Pharma,Inc. | 3.31 Billion JPY | -107.602% |
| Takara Bio Inc. | 123.2 Billion JPY | 94.416% |
| ReproCELL Incorporated | 9.05 Billion JPY | 24.003% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | -153.367% |
| StemCell Institute Inc. | 6.54 Billion JPY | -5.145% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 1.56% |
| CellSeed Inc. | 2.46 Billion JPY | -179.01% |